ROSA POVIONES GARBALOSA: Open Payments
NPI 1316472129 · MIAMI, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,360 in 61 payments from 10 companies in 2025. Trend: 2023 $1,506 · 2024 $951 · 2025 $1,360
Food & beverage: $1,360
| Company | Payments | Amount |
|---|---|---|
| Eisai Inc. | 9 | $289 |
| ABBVIE INC. | 14 | $252 |
| Axsome Therapeutics, Inc. | 11 | $230 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $200 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $143 |
| Almatica Pharma LLC | 3 | $72 |
| Alkermes, Inc. | 3 | $59 |
| E.R. Squibb & Sons, L.L.C. | 2 | $46 |
| Teva Pharmaceuticals USA, Inc. | 2 | $40 |
| Vanda Pharmaceuticals Inc. | 1 | $29 |
Products named: Leqembi, VRAYLAR, Auvelity, CAPLYTA, TRINTELLIX, LOREEV XR, ARISTADA, COBENFY.
Industry payments across FL — which companies pay providers there.
